EUVIMEDEUVIMED entdecken
Open Access

Subtype and Racial Erythema Variation for Cutaneous Lupus Trials

Lillian Xie, Daniella Forman Faden, Caroline J Stone, Lais Lopes Almeida Gomes, Rui Feng, Victoria P Werth

JAMA Dermatology · 2025

DOI: 10.1001/jamadermatol.2024.5190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Lillian Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Erythema, Clinical Trials as Topic, Patient Selection. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Regulatory guidance and standardization of disease outcome measures are essential to improve cutaneous lupus erythematosus (CLE) trial design and enhance the diversity of trial participants.

Objective

To assess variability in erythema presentation across CLE subtypes and among race and ethnicity groups to determine whether these potential differences affect patient eligibility for erythema trials. Design, Setting, and Participants This cross-sectional study included 377 patients with CLE enrolled in the University of Pennsylvania Cutaneous Lupus Erythematosus Database from January 2007 to December 2023. Data analyses were performed from December 2023 to February 2024. Exposure Race and CLE subtype. Main Outcomes and Measures Mean erythema calculated per the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)−Activity total score divided by areas affected; then, the result was categorized as pink (1.00-1.49) or red (≥1.50) as surrogate estimates of scores per the Cutaneous Lupus Activity Investigator Global Assessment (CLA-IGA).

Results

The total study cohort included 377 adult patients with CLE (mean [SD; range] age, 45.2 [14.8; 18.4-88.8] years; 305 females [80.9%] and 72 males [19.1%]; 115 Black [30.5%], 228 White [60.5%], 34 patients of other races [9.0%; Asian, multiple races, Native American/Pacific Islander, or unknown], and 11 of Hispanic/Latino ethnicity [2.9%]). The most common CLE subtype was chronic CLE (CCLE), affecting 243 patients (64.5%), followed by subacute CLE (SCLE) in 103 patients (27.3%) and acute CLE (ACLE) in 31 patients (8.2%). Significant differences were observed in average erythema across subtypes, with mean (SD) SCLE of 1.62 (0.39) and hypertrophic CCLE of 1.78 (0.25) as the only subtypes routinely classified as red. Significant differences were also observed by race and ethnicity: mean (SD) erythema score in White patients was red (1.58 [0.45]) more frequently than in Black patients (1.36 [0.40]) and patients of other races (1.30 [0.39]), in whom, on average, it was scored as pink. Importantly, among patients who would meet typical CLASI entry criteria (score ≥8) for clinical trials, erythema in more Black patients than in White patients was classified as pink (42% [96 patients] vs 24% [28 patients]), which suggests exclusion from trial participation when a baseline of red lesions is required. Conclusions and Relevance The findings of this cross-sectional study suggest that using average erythema scores per the CLA-IGA scale imposes substantial limitations on trial eligibility, specifically by race and subtype. Given the critical need to standardize CLE trial outcome measures and increase diverse representation in clinical trials, our findings support the use of the CLASI as the primary scoring tool to determine erythema trial eligibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousErythemaClinical Trials as TopicPatient SelectionHumansMaleFemaleAdultMiddle AgedCross-Sectional StudiesAgedSeverity of Illness IndexYoung AdultAdolescentAged, 80 and over

Autor:innen und Institutionen

  • Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
  • Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Department of Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Zitieren

APA

Xie, L., Faden, D. F., Stone, C. J., Lopes Almeida Gomes, L., Feng, R., & Werth, V. P. (2025). Subtype and Racial Erythema Variation for Cutaneous Lupus Trials. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.5190

Vancouver

Xie L, Faden DF, Stone CJ, Lopes Almeida Gomes L, Feng R, Werth VP. Subtype and Racial Erythema Variation for Cutaneous Lupus Trials. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.5190

BibTeX
@article{Xie2025,
  author = {Xie, Lillian and Faden, Daniella Forman and Stone, Caroline J and Lopes Almeida Gomes, Lais and Feng, Rui and Werth, Victoria P},
  title = {Subtype and Racial Erythema Variation for Cutaneous Lupus Trials},
  journal = {JAMA Dermatology},
  year = {2025},
  doi = {10.1001/jamadermatol.2024.5190}
}
Kostenlos starten →